The Biotech Growth Trust (LON:BIOG) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

The Biotech Growth Trust PLC (LON:BIOG)’s share price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 861.12 ($10.91) and traded as low as GBX 813.98 ($10.32). The Biotech Growth Trust shares last traded at GBX 819 ($10.38), with a volume of 165,965 shares.

The Biotech Growth Trust Stock Up 0.6 %

The stock’s fifty day moving average is GBX 861.12 and its two-hundred day moving average is GBX 950.80. The company has a current ratio of 0.59, a quick ratio of 0.00 and a debt-to-equity ratio of 11.02. The firm has a market cap of £235.34 million, a P/E ratio of 2.77 and a beta of 0.50.

The Biotech Growth Trust (LON:BIOG) last released its quarterly earnings results on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) earnings per share for the quarter. The Biotech Growth Trust had a net margin of 95.33% and a return on equity of 26.96%.

Insider Buying and Selling

In related news, insider Julie Tankard bought 1,022 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average cost of GBX 972 ($12.32) per share, with a total value of £9,933.84 ($12,590.42). Also, insider Nicola Shepherd purchased 1,000 shares of the business’s stock in a transaction on Monday, January 13th. The stock was bought at an average cost of GBX 846 ($10.72) per share, with a total value of £8,460 ($10,722.43). Insiders acquired a total of 3,222 shares of company stock worth $2,866,584 over the last ninety days. 0.71% of the stock is owned by corporate insiders.

The Biotech Growth Trust Company Profile

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).